telmisartan
4 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
4
Ongoing
0
Recruiting
0
Completed
1
Sites
16
Countries
4
Endpoints
68
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 68 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 0 of 68 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
No normalized metric codes are available for this asset.
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
4 of 4
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| SARTAN-ADTelmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients | Perindopril, telmisartan Alzheimer’s disease | Alzheimer's disease | Ph 2 | Terminated | 10 | Feb 2025 | - | |
| TRIDENT COGTriple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study | telmisartan Mixed / unspecified dementia | Age ≥18 | Ph 3 | Terminated | 4 | Feb 2021 | - | |
| TRIDENT-MRITriple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial Magnetic Resonance Imaging Sub-study | telmisartan Vascular cognitive impairment / dementia | Age ≥18 | Not applicable | Terminated | 3 | Mar 2021 | - | |
| HEARTHealth Evaluation in African Americans Using RAS Therapy | telmisartan Alzheimer’s disease | Family history of Alzheimer’s disease required | Ph 1/2 | Completed | 1 | Apr 2022 | 1 | results |
Showing 1-4 of 4 trials